Abstract | BACKGROUND: Moderate to severe chronic hand dermatitis (CHD) is not well controlled by current medical strategies; however, recent studies have shown significant improvement in patients treated with up to 6 months of oral alitretinoin (9-cis-retinoic acid). The results of longer-term continuous treatment are lacking. OBJECTIVE: To evaluate the long-term safety and efficacy of alitretinoin for the treatment of CHD. METHODS: The Physician's Global Assessment ( PGA) and Modified Total Lesion Symptom Score (MTLSS) were used to assess CHD improvement in three patients treated with alitretinoin (10-30 mg/d). Patients had routine bloodwork and were monitored for adverse events. RESULTS: Significant improvement in MTLSS scores (≈ 76%) was seen at 2 months (p < .002) and maintained for the 3-year treatment period with occasional dosage adjustments. No significant adverse events developed that necessitated treatment withdrawal. CONCLUSION:
Alitretinoin was well tolerated in the treatment of these three CHD patients who were carefully monitored over this prolonged treatment period.
|
Authors | Wayne P Gulliver, Kenneth A Baker |
Journal | Journal of cutaneous medicine and surgery
(J Cutan Med Surg)
2012 Jul-Aug
Vol. 16
Issue 4
Pg. 267-71
ISSN: 1203-4754 [Print] United States |
PMID | 22784520
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Antineoplastic Agents
- Alitretinoin
- Tretinoin
|
Topics |
- Administration, Oral
- Aged
- Alitretinoin
- Antineoplastic Agents
(administration & dosage, therapeutic use)
- Chronic Disease
- Dermatitis
(drug therapy)
- Female
- Hand Dermatoses
(drug therapy)
- Humans
- Male
- Middle Aged
- Treatment Outcome
- Tretinoin
(administration & dosage, therapeutic use)
|